This suggests that stem cell donors harbouring CHEK2 variants may have a comparatively smaller impact than high‐ or intermediate‐risk cancer predisposing gene variants such as DDX41, GATA2 and RUNX1.6, 15. This evidence concerns the gene CHEK2 and cancer.